Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Structural Cardiac Malformations in Spinal Muscular Atrophy; A Case Series
Neuromuscular and Clinical Neurophysiology (EMG)
P8 - Poster Session 8 (8:00 AM-9:00 AM)
1-009
To increase clinician awareness of the association between spinal muscular atrophy (SMA) and structural cardiac malformations by describing a series of cases.

SMA is an autosomal recessive disorder characterized by progressive muscle weakness secondary to degeneration of anterior horn cells.  SMA is caused by loss of survival motor neuron (SMN) protein, encoded by the SMN1 gene.  SMA is the most common genetic cause of infant mortality worldwide.  Several case reports and animal studies show that SMA is not purely a motor neuron disorder and that cardiac malformations can be a part of the disease.   

Retrospective chart review of six patients with SMA and structural heart malformations, focusing on clinical presentation, disease progression and disease complications.

All patients had 0 SMN1 copies and had one or two copies of SMN2 when reported. At the time of genetic testing, all patients had typical findings of SMA.  Echocardiogram findings included hypoplastic aortic arch, coarctation of the aorta, large secundum atrial septal defects, ventricular septal defects, and Tetralogy of Fallot.  Hypotonia was recognized 0 - 113 days after identification of cardiac malformations.  Two patients underwent cardiac surgery prior to the genetic diagnosis of SMA type 0.  Five families ultimately decided to pursue comfort care after receiving aggressive medical treatment.  All patients required full time ventilation in early infancy or died between three weeks and seventeen months of life.

SMA should be considered in a neonate with structural heart disease who has hypotonia and weakness out of proportion to overall degree of illness.  If SMA is a possibility, this association should be discussed with the cardiology team as it might alter management.  Awareness of the diagnosis of SMA as well as the cardiac disease will allow families to make informed decisions about cardiac surgery and new disease-modifying treatments for SMA. 

 

Authors/Disclosures
Natalie M. Manhica (University of Iowa)
PRESENTER
No disclosure on file
Jaehyung Lim, MD (Columbia University Irving Medical Center) No disclosure on file
Susan Matesanz, MD Dr. Matesanz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Matesanz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Matesanz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Atamyo . The institution of Dr. Matesanz has received research support from Sarepta . The institution of Dr. Matesanz has received research support from Pfizer. The institution of Dr. Matesanz has received research support from Genentech/Roche.
Russell Butterfield, MD, PhD, BS (University of Utah) Dr. Butterfield has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Butterfield has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Scholar Rock. Dr. Butterfield has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Reata. The institution of Dr. Butterfield has received research support from NIH. The institution of Dr. Butterfield has received research support from Ionis. The institution of Dr. Butterfield has received research support from CDC.
Seth J. Perlman, MD (Seattle Children's Hospital) Dr. Perlman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Perlman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Solid Biosciences. Dr. Perlman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. The institution of Dr. Perlman has received research support from Scholar Rock. The institution of Dr. Perlman has received research support from Pfizer. The institution of Dr. Perlman has received research support from Sarepta. The institution of Dr. Perlman has received research support from ReveraGen. The institution of Dr. Perlman has received research support from FibroGen. The institution of Dr. Perlman has received research support from PTC Therapeutics. The institution of Dr. Perlman has received research support from CSL Behring. Dr. Perlman has a non-compensated relationship as a Registry Committee Member with Cure SMA that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Perlman has a non-compensated relationship as a Assessment Program Pilot Committee Member with American Board of Psychiatry & Neurology that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.
Timothy E. Lotze, MD, FÂé¶¹´«Ã½Ó³»­ (Texas Children's Hospital) Dr. Lotze has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Department of Justice VICP. The institution of Dr. Lotze has received research support from NIH. The institution of Dr. Lotze has received research support from National MS Society. The institution of Dr. Lotze has received research support from Sarepta Therapeutics. The institution of Dr. Lotze has received research support from PTC THERAPEUTICS. The institution of Dr. Lotze has received research support from Avexis. Dr. Lotze has received publishing royalties from a publication relating to health care. Dr. Lotze has received publishing royalties from a publication relating to health care.
Elizabeth A. Kichula, MD, PhD (Children'S Hospital of Philadelphia) No disclosure on file
No disclosure on file
Katherine D. Mathews, MD, FÂé¶¹´«Ã½Ó³»­ (University of Iowa - Dept of Pediatrics) Dr. Mathews has received personal compensation for serving as an employee of Avidity Bioscience. The institution of Dr. Mathews has received research support from NIH. The institution of Dr. Mathews has received research support from Centers for Disease Control and Prevention. The institution of Dr. Mathews has received research support from Muscular Dystrophy Association . The institution of Dr. Mathews has received research support from Friedreich's Ataxia Research Alliance . The institution of Dr. Mathews has received research support from Sarepta . The institution of Dr. Mathews has received research support from Pfizer. The institution of Dr. Mathews has received research support from Reata . The institution of Dr. Mathews has received research support from PTC Therapeutics, Inc. The institution of Dr. Mathews has received research support from Italfarmaco . The institution of Dr. Mathews has received research support from AMO. The institution of Dr. Mathews has received research support from FibroGen. The institution of Dr. Mathews has received research support from Capricor. The institution of Dr. Mathews has received research support from edgewise. The institution of Dr. Mathews has received research support from biogen.